Solid Biosciences (Nasdaq: SLDB) is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, Solid’s mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with lead gene therapy candidate, SGT-001.
Bain Capital Healthcare
We have built one of the largest and deepest healthcare investing teams in the world. Click here to read more about the breadth and legacy of our efforts.